AMH: A Signal From the Growing Follicle Pool
Anti-Müllerian hormone is a signaling protein made by the ovaries' small, growing egg sacs (granulosa cells of preantral and small antral follicles). It's called "anti-Müllerian" because, in male embryos, AMH from the testes causes the Müllerian ducts to regress, shaping male internal anatomy (Sertoli cells; Müllerian duct regression). In everyday blood testing for adults, AMH mainly reflects ovarian production and is released steadily, changing little across the menstrual cycle.
In the ovary, AMH helps set the pace of follicle development—acting as a local brake that influences how many follicles enter growth and how sensitive they are to pituitary signals (follicular recruitment; FSH sensitivity). Measuring AMH in blood gives a snapshot of how many small follicles are actively present, offering a biological read on the ovaries' egg supply and activity (ovarian reserve; growing follicle pool). This captures the living, working portion of the ovary rather than the silent store, and helps indicate how the ovary may respond to hormonal cues. In early life and in males, AMH mainly reflects activity of the testicular supporting cells that guide development (Sertoli cell function), explaining the hormone's name and broader biological role.
Why Ovarian Reserve Is Worth Measuring
AMH (anti-Müllerian hormone) is a signal from the gonads about how many immature follicles or Sertoli cells are active. In women it reflects the size of the ovarian follicle pool and how responsive the ovary is to pituitary signals; in males, it reflects Sertoli cell function in the testes. Because it links the ovary or testis to the brain's reproductive axis, AMH informs fertility potential, pubertal development, and, indirectly, lifelong bone and metabolic health.
Reading an AMH Value Across the Life Span
Typical values vary by age and lab. In women, levels peak in early adulthood and steadily fall toward menopause; for most, an age-appropriate middle range is expected. In infancy boys have high levels that decline toward low adult male values; girls have low levels in childhood that rise with puberty.
When AMH is low in women, it usually means fewer recruitable follicles—diminished ovarian reserve—from aging or primary ovarian insufficiency. Cycles may shorten or become irregular, and there can be fertility challenges; if estrogen falls early, hot flashes and downstream risks to bone and cardiovascular health may follow. During pregnancy, AMH naturally runs lower. In infants and boys, very low AMH can indicate absent or poorly functioning testes.
When AMH is high in women, it often reflects many small follicles, as seen in polycystic ovary syndrome, with irregular or absent ovulation, acne or excess hair, and increased risks of insulin resistance. Markedly elevated results can be a tumor marker for granulosa cell tumors.
Low values usually reflect a smaller pool of recruitable follicles (diminished ovarian reserve), most often with advancing age and near menopause. They can also follow ovarian surgery, chemotherapy, or genetic ovarian disorders. During pregnancy and with some hormonal contraceptives, AMH often reads lower because follicle recruitment is suppressed. In boys, low AMH can signal impaired Sertoli cell function.
High values usually reflect a larger count of small follicles, often seen in polycystic ovary syndrome, where follicle maturation is stalled. This can associate with irregular cycles and androgen excess. Markedly high results can occur with rare granulosa cell tumors. In male infants and boys, high AMH can be physiologic.
What Can Shift an AMH Reading
Interpretation is age‑ and assay‑dependent; reference intervals vary by lab. AMH is relatively stable across the menstrual cycle but can be lower in pregnancy and with hormonal contraception. Pair with clinical history, ultrasound, and other hormones for context.
Tests That Sharpen the Reproductive Picture Around AMH
AMH connects ovarian or testicular biology to the brain, metabolism, and aging. It complements gonadotropins, sex steroids, ultrasound findings, and clinical history to clarify reproductive timing, detect disorders like PCOS or gonadal dysgenesis, and anticipate health risks tied to the sex‑steroid milieu.
What AMH Can and Cannot Promise
AMH does not measure egg quality or guarantee pregnancy but helps predict ovarian response to stimulation. Being in range suggests an age-appropriate number of small follicles and steady ovarian signaling, supporting regular cycles and a predictable response to fertility medications if needed. In children and men, age‑appropriate AMH supports normal Sertoli cell activity.
FAQs
Anti-Müllerian hormone (AMH) is a signaling protein produced by granulosa cells in the ovaries. In women, AMH reflects the number of small, recruitable follicles—essentially serving as a marker of ovarian reserve. AMH levels help estimate the remaining egg supply and provide insight into reproductive lifespan, fertility potential, and timing of menopause. While AMH is a reliable indicator of egg quantity, it does not measure egg quality or guarantee natural conception. AMH is also used to guide fertility treatments and assess the impact of medical interventions like chemotherapy on ovarian reserve.
AMH testing is a key tool for evaluating ovarian reserve, which is the ovary’s capacity to produce eggs now and in the near future. By measuring AMH levels in the blood, clinicians can estimate the size of the remaining follicle pool. This information helps guide decisions about family planning, egg freezing, and fertility treatments such as IVF. AMH testing is especially useful for spotting diminished ovarian reserve before symptoms appear and for tailoring IVF stimulation protocols to minimize the risk of low or excessive ovarian response.
Low AMH levels in women typically indicate a reduced ovarian reserve, meaning fewer small follicles are available for recruitment. This is common with aging or after ovarian injury (e.g., surgery, chemotherapy, or radiation). Low AMH is associated with a shorter reproductive window, higher FSH levels, and a lower response to fertility stimulation. While cycles may remain regular initially, women may experience lighter or skipped periods and menopausal symptoms as estrogen declines. Low AMH does not directly measure egg quality or guarantee infertility.
High AMH levels in women often reflect an increased number of small ovarian follicles, a hallmark of polycystic ovary syndrome (PCOS). In PCOS, follicle maturation is disrupted, leading to infrequent ovulation, irregular cycles, and symptoms like acne or hirsutism. High AMH is also linked to insulin resistance and long-term metabolic risks. Rarely, very high AMH can indicate ovarian granulosa cell tumors. High AMH is normal in adolescence and tends to decrease during pregnancy.
AMH testing is crucial in fertility treatment planning, especially for in vitro fertilization (IVF). AMH levels help predict how the ovaries will respond to stimulation, allowing clinicians to tailor medication dosing and minimize the risk of low or excessive ovarian response. By assessing ovarian reserve, AMH testing informs decisions about egg freezing, timing of treatment, and expectations for success. It is often interpreted alongside other markers like antral follicle count, FSH, and patient age.
Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.
We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.
References
- Moolhuijsen, L. M. E., & Visser, J. A. (2020). Anti-Müllerian hormone and ovarian reserve: Update on assessing ovarian function. The Journal of Clinical Endocrinology & Metabolism, 105(11), 3361-3373. https://doi.org/10.1210/clinem/dgaa513
- Dewailly, D., Andersen, C. Y., Balen, A., Broekmans, F., Dilaver, N., Fanchin, R., Griesinger, G., Kelsey, T. W., La Marca, A., Lambalk, C., Mason, H., Nelson, S. M., Visser, J. A., Wallace, W. H., & Anderson, R. A. (2014). The physiology and clinical utility of anti-Müllerian hormone in women. Human Reproduction Update, 20(3), 370-385. https://doi.org/10.1093/humupd/dmt062
- Harlow, S. D., Gass, M., Hall, J. E., Lobo, R., Maki, P., Rebar, R. W., Sherman, S., Sluss, P. M., & de Villiers, T. J. (2012). Executive summary of the Stages of Reproductive Aging Workshop + 10: Addressing the unfinished agenda of staging reproductive aging. Menopause, 19(4), 387-395. https://doi.org/10.1097/gme.0b013e31824d8f40
- Teede, H. J., Tay, C. T., Laven, J., Dokras, A., Moran, L. J., Piltonen, T. T., Costello, M. F., Boivin, J., Redman, L. M., Boyle, J. A., Norman, R. J., Mousa, A., & Joham, A. E. (2023). Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertility and Sterility, 120(4), 767-793. https://doi.org/10.1016/j.fertnstert.2023.07.025
- Marques, P., De Sousa Lages, A., Skorupskaite, K., Rozario, K. S., Anderson, R. A., & George, J. T. (2024). Physiology of GnRH and gonadotrophin secretion. In Endotext. MDText.com. https://www.ncbi.nlm.nih.gov/books/NBK279070/






































.avif)
